AutoIVF discloses $1.5 million private securities offering in SEC Form D

AutoIVF, Inc., a Delaware corporation based in Natick, Massachusetts, filed a Form D notice with the Securities and Exchange Commission disclosing an exempt securities offering. The company is headquartered at 22 Strathmore Road, Suite 317, in Natick, Massachusetts.¹

The filing lists the date of first sale as August 7, 2026.¹ The total offering amount and total amount sold were each listed as $1,500,000, with $0 remaining to be sold.¹ The filing states that 15 investors had already invested in the offering.¹

AutoIVF claimed the Rule 506(b) exemption under federal securities law.¹ The securities offered were described as a security to be acquired upon exercise of an option, warrant or other right to acquire a security, along with an "Other" category identified as a Simple Agreement for Future Equity.¹ The company indicated the offering was not made in connection with a business combination transaction such as a merger or acquisition.¹

The filing lists a minimum investment of $0 accepted from any outside investor.¹ The company reported $0 in sales commissions and finders' fees expenses.¹ Proceeds directed toward payments to executive officers, directors or promoters were listed as $0.¹

AutoIVF identified its industry group as Biotechnology within the Health Care category.¹ The company selected "Decline to Disclose" for its issuer size, covering both revenue range and aggregate net asset value range.¹

The filing lists Ravi Kapur, Michael Alper, Mitchell Sayare, David Sable and Erin Schardt as related persons, with Kapur and Sayare identified as both executive officers and directors, and Alper, Sable and Schardt identified as directors.¹ Ravi Kapur, listed as CEO, signed the notice on September 25, 2026.¹